Miami, FL (PRWEB) June 17, 2012
A newly published study in patients having early and intermediate age-related maculate degeneration (AMD), a major cause of visual impairment in those over 50 years of age, suggests that Alpha Lipoic Acid, a nutritional antioxidant, may have a possible preventive role in the development of AMD. Agreeing with this study, Nutri-Med logic Corp adds that another very recent and landmark study by the Department of Ophthalmology, University of Alberta, Edmonton, Alberta, Canada, also suggests that supplementation of Omega-3 fatty acids, an anti-inflammatory nutrient, resulted in a protective application against age-related retina functional losses.
This new study, which incorporated patients between 50-75, found that the administration of Alpha Lipoic Acid (LA) resulted in a statistically significant increase in the anti-oxidant defense of the LA group, suggesting that Alpha Lipoic Acid could propose a preventive role in the development of the dry AMD.
The dry AMD is the results of the atrophy of the retinal pigment epithelial (a cellular layer of the retina), in another word the loss of photoreceptor cells (vision loss). The Retinal Pigment Epithelial shields the retina from excess incoming light as well as supplying Omega-3 fatty acids (DHA), which are the sole fatty acids incorporated into the cellular membranes of the eyes.
Cellular oxidative stress plays a key and fundamental role in retinal pigment epithelial cell death during aging, thus leading to the development of AMD. (1)
Superoxide Dismutase (SOD) is one of the most important anti-oxidant defense systems that shield the human body from oxidative stress and this new study found that the application of Alpha Lipoic Acid resulted in the increased activity of SOD. In United States, Alpha Lipoic Acid is classified as a nutrient (dietary supplement).
While this finding proposes an important dietary intervention for Alpha Lipoic Acid and AMD, another very important study by the Department of Ophthalmology of the University of Alberta, Canada, found that 1-6 months trial of Omega-3 (DHA) dietary supplementation resulted in its increased retina levels, preserving the retinal pigment epithelial function and, further, the 6-12 months trial led to maintained outer and inner retina function.
The increased anti-oxidant defense (SOD) by Alpha Lipoic Acid do suggests a lesser oxidative stress and thus a diminished premature retinal pigment epithelial cell death, interestingly the very cell line that supplies Omega-3 fatty acids of DHA.
The retina has the highest concentration of DHA Omega-3 fatty acids, the precursor to Docosanoids, which produce neuroprotectin D1, inhibiting premature apoptosis (cell death) and oxidative-stress-mediated pro-inflammatory gene induction. (2)
In conclusion, Nutri-Med Logic Corp. agreeing with new study, adds that while the supplementation of R-Alpha Lipoic Acid, an anti-oxidant nutrient, would be beneficial in AMD but a concurrent supplementation of Omega-3, an anti-inflammatory nutrient, would propose additional benefits.
Nutri-Med Logic Corp is the producer of the Natural, Balanced, Deodorized, Concentrated and Pharmaceutical Grade Omega-3.
Nutri-Med Logic Corp is also a producer of dietary supplements such as a Pharmaceutical Grade R-Alpha Lipoic Acid (the natural type of Lipoic Acid), a universal anti-oxidant and the dietary supplement of choice for the Diabetics, in Germany for decades;
Producer of PolyEnylPhosphatidylCholine (PPC 425mg), an extract of soy, a pure and effective dietary source of choline and the recommended dietary supplement for those with Fatty Liver and Alcoholic Liver Disease, in Europe for decades.
Nutri-Med Logic Corp invites you to visit its News Archives and Review its News Releases on other potential benefits of R-Alpha Lipoic Acid and What is Omega-3 Good For.
Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.
It must be noted that the studies, statements or sources above or below have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the dietary supplements, stated herein, nor equate their supplementation to prevention, treatment or cure.
1. PPAR Research. Volume 2008 (2008), Article ID 720163
2. Trends in Neuroscience. 2006 May;29(5):263-71